Acute Promyelocytic Leukemia Overview

Save information for later
Sign Up

Learn About Acute Promyelocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Promyelocytic Leukemia?
Acute promyelocytic leukemia (APL) is an aggressive type of acute myeloid leukemia in which there are too many immature blood-forming cells (promyelocytes) in the blood and bone marrow. This build up of promyelocytes leads to a shortage of normal white and red blood cells and platelets in the body. The signs and symptoms of APL include an increased risk to both bleed and form blood clots. Individuals may also experience excessive tiredness, pain in affected areas, loss of appetite, and weight loss. It is caused by a genetic change that is acquired over a person's lifetime, usually involving a translocation between chromosomes 15 and 17.
What are the alternative names for Acute Promyelocytic Leukemia?
  • Acute promyelocytic leukemia
  • AML M3
  • AML with t(15;17)(q22;q12);(PML/RARalpha) and variants
  • APML
  • Acute myeloblastic leukemia 3
  • Acute myeloblastic leukemia type 3
  • Acute myeloid leukemia with t(15;17)(q22;q12);(PML/RARalpha) and variants
Who are the top Acute Promyelocytic Leukemia Local Doctors?
Elite in Acute Promyelocytic Leukemia
Dr. Martin S. Tallman
Hematology | Hematology Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Martin S. Tallman
Hematology | Hematology Oncology
675 N Saint Clair St, Galter 21-100, 
Chicago, IL 
312-695-0990
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Martin Tallman is a Hematologist and a Hematologist Oncology provider in Chicago, Illinois. Dr. Tallman and is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Tallman is currently accepting new patients.

Elite in Acute Promyelocytic Leukemia
Dr. Bayard L. Powell
Oncology | Hematology
Elite in Acute Promyelocytic Leukemia
Dr. Bayard L. Powell
Oncology | Hematology

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bayard Powell is an Oncologist and a Hematologist in Winston Salem, North Carolina. Dr. Powell and is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Powell is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Promyelocytic Leukemia
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology
Elite in Acute Promyelocytic Leukemia
Dr. Tapan M. Kadia
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia and is rated as an Elite provider by MediFind in the treatment of Acute Promyelocytic Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

View All Doctors
What are the latest Acute Promyelocytic Leukemia Clinical Trials?
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)
Enrollment Status: Recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Who is this study for: Child to adult patients with Recurrent or Refractory Solid Tumors or Acute Leukemia
Enrollment Status: Recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: PLX3397
Study Phase: Phase 1

Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center